Posted in Antibodies, Assay Kits, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, DNA Testing, Elisa Kits, PCR, Peptides, Reagents, Recombinant Proteins, Ria Kits, RNA, Test Kits
Combined Placental Maternal Floor Infarction and Cytomegalovirus Placentitis: A Case Report
Mother’s infarction (MFI) and Masif Fibrin Perive (MPFD) deposition (MPFD) are unusual, related to the condition of the secondary placenta of trophoblastic cell damage. The etiology is unknown but MPFD / MFI is associated with adverse obstetric results and a significant risk of repeatment. Case Report: We report the MPFD / MFI case related to placentitis Cytomegalovirus (CMV). A 27-year-old mother gave birth to a man’s fetus born with a postmortem diagnosis of default CMV.
The placenta shows limfohistiocial villitis with isolated CMV inclusion, in combination with MFI. Villitis has an intermediary feature between unclean cmv placentitis and ethiological villitis (Vue). Conclusion: Vue is considered a reaction of an anti-fetal immune mother who resembles the refusal of allograft. We postulate that viral infections in our case may have triggered this immune response, considering that CMV antigens are known to be crossing with some human antigens, especially HLA. The next trophoblastic cell damage can then lead to MFI / MFPD.
Hemolytic uremic syndrome and atypical nephrotic syndrome associated with cytomegalovirus infection
Atypical hemolytic uremic syndrome (ahus) is a rare disease. It is produced from the disregulation of alternative complementary pathways on the cell surface which causes endothelial damage. Increasing evidence evidence, this disorder is for mutations in the complementary regulator gene or with autoantibodies to complementary factors. This mutation has incomplete penetration and variable phenotypes.
Cytomegalovirus (CMV) is endemic throughout the world, and the incidence of severe CMV disease in immunocompetent adults seems to be greater than previously thought. Ahus and nephrotic syndrome associated with CMV infection rarely occur. The identification of triggers for the manifestation of the ahus in patients who are vulnerable genetics is very important because this allows faster clinical treatment and improvement initiations. We reported a case of a man with the removal of homozygous CFHR3-1 whose initial presentation was ahus and nephrotic syndrome associated with CMV infection.
IgA binds epitop glycoprotein B and neutralizes human cytomegalovirus
Human Cytomegalovirus (HCMV) is a pathogen everywhere that has the potential for pathogens in immunosuppression individuals and pregnant women during primary infections. HCMV Envelope Glycoprotein B (GB) facilitates virus entries into all types of cells and induces strong immune responses. Epitope AD-2 is a very preserved GB Linear GB epitope and the critical target for antibodies, only 50% of seropositive individuals that make IgG antibodies to this site and the rib response has not been fully investigated.
This study aims to compare IGG and IGA responses to GB and Epitop AD-2 in individuals who are exposed to naturally and those who receive the recombinant Ajuvant GB / MF59 vaccine. Thus, seropositive individual vaccination increases the existing IGA and GB IGG levels and induces the rib response and specific IGG de Novo GB on seronegative receivers. The existing IgG response and AD-2 ribs were driven by vaccination but the response of De Novo AD-2 was not detected. Individuals exposed naturally have the dominant IgG response to GB and AD-2 compared to weaker rib responses and variables, although significant rib response to AD-2 was observed in the ASI ASI sample.
All antibodies tie the AD-2 contain a light chain of kappa while the use of a balanced capa / lambda light chain is found for those who bind to GB. The V-region matches the specific recombinant IGG AD-2 and ribs are bound to GB and AD-2 and neutralize HCMV infection in vitro. Overall, this result shows that even though the human IGG response dominates, class IGA antibodies against AD-2 are significant components of breast milk that can function to protect neonates from HCMV.
Cytomegalovirus After a kidney transplant in 2020: moving towards personalized prevention
Cytomegalovirus (CMV) – Close complications after kidney transplants remain a substantial challenge. Instead of applying a preventive strategy to all risky patients, we can now adjust our strategies at the individual patient level. The prophylaxis of antivirus or strict pre-emptive strategies may be optimal for patients with the highest risk for CMV, while lower risk patients can be profitable especially from pre-emptive monitoring and therapeutic administration only if needed.
CMV Special T-Testing may be useful to improve the determination of CMV risk in pre-transplants, and to guide decisions about the need for antivirus therapy or duration. Immunosupressive regimens including the target of the Rapamycin mammal inhibitor reduces the risk of CMV and thus can be an interesting choice in some patients. The new antivirus agent further expanded our therapy arsenal in the near future, and the prospect of CMV vaccination and remove cell therapy seems to be on the horizon.

Cytomegalovirus Pre-Transplant Immunity and Risk of Viral Reactivation After Lung Transplantation: Prospective Cohort Study
Cytomegalovirus (CMV) remains a significant burden on the recipient of the lung transplant. Disadvantages in the immunity of the TP-transplant increases the risk of complications related to CMV. However, it is not clear if the underlying pre-transplant immunity increases risk. To assess this, we recruit 39 lung transplant patients and do quantiferon-CMV in their peripheral blood. More than a third of prospective cmv-seropositive transplant receivers are non-imun-reactive CMV (CMV-NIR) pre-transplant.
Hba Polyclonal Antibody |
A53679 |
EpiGentek |
-
EUR 684.66
-
Ask for price
-
Ask for price
-
EUR 423.50
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
HBA Polyclonal Antibody |
ES11261-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against HBA from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
HBA Polyclonal Antibody |
ES11261-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against HBA from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
Human Brain Astrocytes (HBA) |
HMP202 |
Neuromics |
500,000+ cells - Frozen |
EUR 1296 |
Hba Antibody, HRP conjugated |
1-CSB-PA010147LB01MO |
Cusabio |
|
|
|
Description: A polyclonal antibody against Hba. Recognizes Hba from Mouse. This antibody is HRP conjugated. Tested in the following application: ELISA |
Hba Antibody, FITC conjugated |
1-CSB-PA010147LC01MO |
Cusabio |
|
|
|
Description: A polyclonal antibody against Hba. Recognizes Hba from Mouse. This antibody is FITC conjugated. Tested in the following application: ELISA |
Hba Antibody, Biotin conjugated |
1-CSB-PA010147LD01MO |
Cusabio |
|
|
|
Description: A polyclonal antibody against Hba. Recognizes Hba from Mouse. This antibody is Biotin conjugated. Tested in the following application: ELISA |
Hba-a2 sgRNA CRISPR Lentivector (Rat) (Target 2) |
K6915803 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-x sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K3266403 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-a2 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K3179403 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-a1 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K3332403 |
ABM |
1.0 ug DNA |
EUR 184.8 |
HBA ELISA Kit (Mouse) (OKEH05810) |
OKEH05810 |
Aviva Systems Biology |
96 Wells |
EUR 794.4 |
Description: Description of target: Involved in oxygen transport from the lung to the various peripheral tissues. ;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.84 ng/mL |
HBA ELISA Kit (Bovine) (OKEH03848) |
OKEH03848 |
Aviva Systems Biology |
96 Wells |
EUR 934.8 |
Description: Description of target: Involved in oxygen transport from the lung to the various peripheral tissues.;Species reactivity: Bovine;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.59 ng/mL |
Hba-a2 Recombinant Protein (Rat) |
RP204248 |
ABM |
100 ug |
Ask for price |
Hba-x Recombinant Protein (Mouse) |
RP140996 |
ABM |
100 ug |
Ask for price |
Mouse Hemoglobin subunit alpha (Hba) |
1-CSB-YP010147MO |
Cusabio |
-
EUR 604.80
-
EUR 318.00
-
EUR 2198.40
-
EUR 915.60
-
EUR 1459.20
-
EUR 400.80
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Mouse Hemoglobin subunit alpha(Hba) expressed in Yeast |
Mouse Hemoglobin subunit alpha (Hba) |
1-CSB-EP010147MO |
Cusabio |
-
EUR 606.00
-
EUR 318.00
-
EUR 2192.40
-
EUR 919.20
-
EUR 1461.60
-
EUR 402.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Mouse Hemoglobin subunit alpha(Hba) expressed in E.coli |
Hba-a1 Recombinant Protein (Mouse) |
RP140990 |
ABM |
100 ug |
Ask for price |
Hba-a2 Recombinant Protein (Mouse) |
RP140993 |
ABM |
100 ug |
Ask for price |
Hemoglobin Subunit Alpha (Hba) Antibody |
20-abx109857 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Hba Polyclonal Antibody, HRP Conjugated |
A53680 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
Hba Polyclonal Antibody, FITC Conjugated |
A53681 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
Hba Polyclonal Antibody, Biotin Conjugated |
A53682 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
Rat Hemoglobin subunit alpha-1/2, HBA ELISA Kit |
ELA-E0517r |
Lifescience Market |
96 Tests |
EUR 1063.2 |
Hba-a2 ORF Vector (Rat) (pORF) |
ORF068084 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Hba-x ORF Vector (Mouse) (pORF) |
ORF047000 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Hba-a1 ORF Vector (Mouse) (pORF) |
ORF046998 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Hba-a2 ORF Vector (Mouse) (pORF) |
ORF046999 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Hba-a2 sgRNA CRISPR Lentivector set (Rat) |
K6915801 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Hba-x sgRNA CRISPR Lentivector set (Mouse) |
K3266401 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Hba-a2 sgRNA CRISPR Lentivector set (Mouse) |
K3179401 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Hba-a1 sgRNA CRISPR Lentivector set (Mouse) |
K3332401 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Human Hemoglobin subunit alpha, HBA ELISA Kit |
ELA-E05171h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Mouse Hemoglobin subunit alpha, HBA ELISA Kit |
ELA-E0517m |
Lifescience Market |
96 Tests |
EUR 1038 |
Bovine HBA/ Hemoglobin subunit alpha ELISA Kit |
E0304Bo |
Sunlong |
1 Kit |
EUR 860.4 |
Bovine Hemoglobin subunit alpha, HBA ELISA Kit |
ELA-E0517b |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Canine Hemoglobin subunit alpha, HBA ELISA Kit |
ELA-E0517d |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Chicken Hemoglobin subunit alpha, HBA ELISA Kit |
ELA-E0517c |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Porcine Hemoglobin subunit alpha, HBA ELISA Kit |
ELA-E0517p |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Porcine Hemoglobin subunit alpha(HBA)ELISA Kit |
YLA0356PO-96T |
Shanghai YL Biotech |
96T |
EUR 618.75 |
Hba-x 3'UTR GFP Stable Cell Line |
TU159377 |
ABM |
1.0 ml |
Ask for price |
Hba-a1 3'UTR GFP Stable Cell Line |
TU159375 |
ABM |
1.0 ml |
Ask for price |
Hba-a2 3'UTR GFP Stable Cell Line |
TU159376 |
ABM |
1.0 ml |
Ask for price |
Hba-a2 3'UTR GFP Stable Cell Line |
TU255653 |
ABM |
1.0 ml |
Ask for price |
Hba-a2 Protein Vector (Rat) (pPM-C-HA) |
PV272336 |
ABM |
500 ng |
EUR 723.6 |
Hba-x Protein Vector (Mouse) (pPM-C-HA) |
PV188000 |
ABM |
500 ng |
EUR 723.6 |
Hba-a2 Protein Vector (Rat) (pPB-C-His) |
PV272334 |
ABM |
500 ng |
EUR 723.6 |
Hba-a2 Protein Vector (Rat) (pPB-N-His) |
PV272335 |
ABM |
500 ng |
EUR 723.6 |
Hba-a2 Protein Vector (Rat) (pPM-C-His) |
PV272337 |
ABM |
500 ng |
EUR 723.6 |
Hba-a1 Protein Vector (Mouse) (pPM-C-HA) |
PV187992 |
ABM |
500 ng |
EUR 723.6 |
Hba-a2 Protein Vector (Mouse) (pPM-C-HA) |
PV187996 |
ABM |
500 ng |
EUR 723.6 |
Hba-x Protein Vector (Mouse) (pPB-C-His) |
PV187998 |
ABM |
500 ng |
EUR 723.6 |
Hba-x Protein Vector (Mouse) (pPB-N-His) |
PV187999 |
ABM |
500 ng |
EUR 723.6 |
Hba-x Protein Vector (Mouse) (pPM-C-His) |
PV188001 |
ABM |
500 ng |
EUR 723.6 |
Hba-x 3'UTR Luciferase Stable Cell Line |
TU109377 |
ABM |
1.0 ml |
Ask for price |
Hba-a1 Protein Vector (Mouse) (pPB-C-His) |
PV187990 |
ABM |
500 ng |
EUR 723.6 |
Hba-a1 Protein Vector (Mouse) (pPB-N-His) |
PV187991 |
ABM |
500 ng |
EUR 723.6 |
Hba-a1 Protein Vector (Mouse) (pPM-C-His) |
PV187993 |
ABM |
500 ng |
EUR 723.6 |
Hba-a2 Protein Vector (Mouse) (pPB-C-His) |
PV187994 |
ABM |
500 ng |
EUR 723.6 |
Hba-a2 Protein Vector (Mouse) (pPB-N-His) |
PV187995 |
ABM |
500 ng |
EUR 723.6 |
Hba-a2 Protein Vector (Mouse) (pPM-C-His) |
PV187997 |
ABM |
500 ng |
EUR 723.6 |
Hba-a1 3'UTR Luciferase Stable Cell Line |
TU109375 |
ABM |
1.0 ml |
Ask for price |
Hba-a2 3'UTR Luciferase Stable Cell Line |
TU109376 |
ABM |
1.0 ml |
Ask for price |
Hba-a2 3'UTR Luciferase Stable Cell Line |
TU205653 |
ABM |
1.0 ml |
Ask for price |
Hba-a2 sgRNA CRISPR Lentivector (Rat) (Target 1) |
K6915802 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-a2 sgRNA CRISPR Lentivector (Rat) (Target 3) |
K6915804 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
K6915807 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-x sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K3266402 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-x sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K3266404 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-x sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
K3266407 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-a2 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K3179402 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-a2 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K3179404 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-a1 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K3332402 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-a1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K3332404 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
K3179407 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-a1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
K3332407 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Anti-HBA antibody |
STJ192419 |
St John's Laboratory |
200 µl |
EUR 236.4 |
Description: Unconjugated Rabbit polyclonal to HBA |
Hba-a2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV678205 |
ABM |
1.0 ug DNA |
EUR 616.8 |
Hba-a2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV678209 |
ABM |
1.0 ug DNA |
EUR 616.8 |
Hba-a2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
LV678210 |
ABM |
1.0 ug DNA |
EUR 616.8 |
Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
K6915805 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Hba-x sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
K3266405 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
K3179405 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Hba-a1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
K3332405 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
K6915806 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
K6915808 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-x sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K3266406 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-x sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
K3266408 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K3179406 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-a2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
K3179408 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-a1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K3332406 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-a1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
K3332408 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Hba-a2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
LV678206 |
ABM |
1.0 ug DNA |
EUR 616.8 |
Hba-a2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
LV678207 |
ABM |
1.0 ug DNA |
EUR 686.4 |
Hba-a2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
LV678208 |
ABM |
1.0 ug DNA |
EUR 686.4 |
Hemoglobin subunit alpha Antibody / HBA1/2 |
RQ6772 |
NSJ Bioreagents |
100ug |
EUR 356.15 |
Description: The human alpha globin gene cluster located on chromosome 16 spans about 30 kb and includes seven loci: 5'- zeta - pseudozeta - mu - pseudoalpha-1 - alpha-2 - alpha-1 - theta - 3'. The alpha-2 (HBA2) and alpha-1 (HBA1) coding sequences are identical. These genes differ slightly over the 5' untranslated regions and the introns, but they differ significantly over the 3' untranslated regions. Two alpha chains plus two beta chains constitute HbA, which in normal adult life comprises about 97% of the total hemoglobin; alpha chains combine with delta chains to constitute HbA-2, which with HbF (fetal hemoglobin) makes up the remaining 3% of adult hemoglobin. Alpha thalassemias result from deletions of each of the alpha genes as well as deletions of both HBA2 and HBA1; some nondeletion alpha thalassemias have also been reported. |
HBA1 sgRNA CRISPR Lentivector (Human) (Target 2) |
K0931303 |
ABM |
1.0 ug DNA |
EUR 184.8 |
HBA2 sgRNA CRISPR Lentivector (Human) (Target 2) |
K0931403 |
ABM |
1.0 ug DNA |
EUR 184.8 |
HBA2 Hemoglobin, Alpha 2 Human Recombinant Protein |
PROTP69905 |
BosterBio |
Regular: 20ug |
EUR 380.4 |
Description: HBA2 Human Recombinant produced in E. coli is a single polypeptide chain containing 179 amino acids (1-142) and having a molecular mass of 19.5 kDa.;HBA2 is fused to a 37 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
Rat Hemoglobin Subunit Alpha 1/2 (HBA1) ELISA Kit |
abx256288-96tests |
Abbexa |
96 tests |
EUR 801.6 |
|
Rat Hba1/ Hemoglobin subunit alpha-1/2 ELISA Kit |
E0438Ra |
Sunlong |
1 Kit |
EUR 685.2 |
The CMV-NIR status is associated with the incidence of CMV reactivation transplantation which is significantly higher, indicating that the immunity of CMV dysfunctional in prospective lung transplant recipients is associated with an increased risk of viral viral-transplant reactivation.
Keywords: cytomegalovirus; T-cell immunity; solid organ transplant; Virus reactivation.